TG Therapeutics to Highlight BRIUMVI at Multiple Sclerosis Forum
NEW YORK — TG Therapeutics, Inc. (NASDAQ: TGTX) is excited to announce a comprehensive schedule of presentations showcasing key data from its pivotal trials involving BRIUMVI (ublituximab-xiiy) for patients managing relapsing forms of multiple sclerosis (RMS). This presentation will take place during the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, scheduled for February 27 – March 1, 2025.
Key Presentations Scheduled
These presentations will cover vital insights derived from the ULTIMATE I & II Phase 3 studies and the ENHANCE Phase 3b trial. With a growing patient population facing the challenges of RMS, these findings are critical for informing treatment decisions and improving patient outcomes.
Highlighted Poster Presentations
One of the key presentations is titled "Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study." It will occur on Thursday, February 27, 2025, from 6:45 PM to 7:30 PM ET, showcasing the latest data on infusion protocols and their effects on patient comfort and efficacy.
Another significant presentation is expected to generate interest: "The Design of a Study to Evaluate Fc Biology and Genetic Diversity in Multiple Sclerosis." This session will take place on the same day from 6:00 PM to 6:45 PM ET, led by Nancy Monson, Ph.D., from the University of Texas Southwestern Medical Center.
Overview of Additional Presentations
Additional insights into BRIUMVI’s efficacy will be highlighted in the presentation titled "Real-World Ublituximab Experience at a Single US MS Center". Presented by Dr. John Foley, another critical session on February 28, 2025, aims to discuss real-world usage and patient responses to BRIUMVI in clinical settings.
About the ULTIMATE I & II Phase 3 Trials
ULTIMATE I & II are pivotal double-blind, randomized trials examining BRIUMVI’s effectiveness compared to teriflunomide. These trials enrolled over 1,000 RMS patients across multiple countries and evaluated the therapy over a 96-week period. Patients were carefully selected based on their disease activity, which significantly contributes to the robustness of the results.
BRIUMVI: A Cutting-Edge Treatment
BRIUMVI is an innovative monoclonal antibody designed specifically to target CD20-expressing B-cells, an essential component in the management of autoimmune diseases like RMS. Its unique formulation enables effective B-cell depletion, allowing for better management of the disease with potentially fewer side effects.
Importance for Patients with Multiple Sclerosis
For adults experiencing RMS, BRIUMVI offers a new option as it caters to various forms of the disease, including clinically isolated syndrome and active secondary progressive disease. With nearly 1 million individuals diagnosed with MS in the U.S. alone, advancements like BRIUMVI are crucial in providing effective treatment protocols.
Further Information and Resources
Following the forum, detailed resources regarding the presentations will be made available on TG Therapeutics’ official website, particularly within the Publications section. This will include easy access to all relevant data discussed during the forum.
Frequently Asked Questions
What studies will be presented at the ACTRIMS Forum?
Key studies include data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial focusing on BRIUMVI.
Who is the lead author for the presentations?
The lead author for one of the prominent studies is Dr. John Foley, affiliated with Rocky Mountain Multiple Sclerosis.
What is BRIUMVI approved for?
BRIUMVI is approved for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome.
When will the presentations occur?
The presentations are scheduled from February 27 to March 1, 2025, during the ACTRIMS annual forum.
Where can I find more information?
For further information, visit the TG Therapeutics website or refer to the ACTRIMS meeting resources.
